TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategy Phase III Intergroup Study for Chemotherapy of the Metastatic or Locally Advanced Cancers of the Stomach
Brief Summary: The purpose of this study is to compare the effectiveness of 2 different sequences of polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 and cisplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: TS-1 | Intervention Type: DRUG; Name: TS-1 and cisplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: TS-1; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ECC | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: FOLFIRI | Intervention Type: DRUG; Name: ECC; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel + S-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-1 | Intervention Type: DRUG; Name: docetaxel + S-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: S-1; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy
Brief Summary: This is an open label phase I/II clinical trial to assess safety, tolerability and potential effect on SMN mRNA and protein in vivo of a compound in which preliminary evidence supports a potential effect on SMN levels in vitro.


Options:
A: Arm Label: Nusinersen 6 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Nusinersen 12 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Nusinersen 12 mg, Nusinersen 6 mg
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Intervention Type: BIOLOGICAL; Name: AVXS-101; Assigned to Arm(s): Cohort 1, Cohort 2
C: Arm Label: Nusinersen; Type: EXPERIMENTAL; Interventions: Drug: Nusinersen | Intervention Type: DRUG; Name: Nusinersen; Assigned to Arm(s): Nusinersen
D: Intervention Type: DRUG; Name: Valproic Acid; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy
Brief Summary: This is an open label phase I/II clinical trial to assess safety, tolerability and potential effect on SMN mRNA and protein in vivo of a compound in which preliminary evidence supports a potential effect on SMN levels in vitro.


Options:
A: Intervention Type: DRUG; Name: Valproic Acid; Assigned to Arm(s): N/A
B: Arm Label: Nusinersen 6 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Nusinersen 12 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Nusinersen 12 mg, Nusinersen 6 mg
C: Arm Label: Cohort 1 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 2 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 3 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 4 (n=10); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Cohort 1 (n=6), Cohort 2 (n=6), Cohort 3 (n=6), Cohort 4 (n=10)
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Intervention Type: BIOLOGICAL; Name: AVXS-101; Assigned to Arm(s): Cohort 1, Cohort 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proton Pump Inhibitors in Conjunction to Endoscopic Therapy for Bleeding Peptic Ulcers: a Randomized Clinical Trial of High vs Standard Doses
Brief Summary: High intravenous dosage of Proton Pump Inhibitors is not better than standard dosage in bleeding peptic ulcers successfully treated by endoscopic therapy


Options:
A: Intervention Type: DRUG; Name: omeprazole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pantoprazole; Assigned to Arm(s): N/A
B: Arm Label: lansoprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: lansoprazole | Arm Label: esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole | Intervention Type: DRUG; Name: lansoprazole; Assigned to Arm(s): lansoprazole | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): esomeprazole
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omeprazole | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Pimozide Augmentation for Clozapine Partial Response
Brief Summary: This is a 12 week outpatient study for patients with schizophrenia who are on Clozapine, but continue to experience symptoms. The purpose of this project is to find out if small doses of pimozide (an antipsychotic medication, taken by mouth) will be helpful in reducing symptoms (such as hearing voices, having trouble in organizing your thoughts, lack of interest in life events and social activities), compared to placebo (an inactive substance, "sugar pill"), when added to clozapine in patients with schizophrenia.

The participant will be asked to come in once a week to meet with the research staff and study doctor. The participant will continue to see your regular clinician during this study for all normal appointments. The participant will remain on your current medications throughout the study. During the study you will be randomly selected to be put on a small dose of Pimozide or placebo.


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperdal | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Risperdal; Assigned to Arm(s): Active
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pimozide | Intervention Type: DRUG; Name: Pimozide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A
D: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN
Brief Summary: About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.

Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.

Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.

Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.


Options:
A: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
B: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC
C: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diabetes Peer Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Peer Counseling | Intervention Type: BEHAVIORAL; Name: Diabetes Peer Counseling; Assigned to Arm(s): Diabetes Peer Counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN
Brief Summary: About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.

Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.

Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.

Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.


Options:
A: Arm Label: Interactive SMS; Type: EXPERIMENTAL; Interventions: Other: Interactive SMS | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Interactive SMS; Assigned to Arm(s): Interactive SMS | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
B: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Home BP;secure messaging;pharmaceutical care;; Assigned to Arm(s): N/A
D: Arm Label: Feedback; Type: EXPERIMENTAL; Interventions: Device: Feedback | Arm Label: Demonstration; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Feedback; Assigned to Arm(s): Feedback | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Demonstration

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN
Brief Summary: About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.

Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.

Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.

Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.


Options:
A: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
B: Arm Label: State of the Art strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: state-of-the art strategy and extented strategy | Arm Label: extended strategy; Type: EXPERIMENTAL; Interventions: Behavioral: state-of-the art strategy and extented strategy | Intervention Type: BEHAVIORAL; Name: state-of-the art strategy and extented strategy; Assigned to Arm(s): State of the Art strategy, extended strategy
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
D: Intervention Type: BEHAVIORAL; Name: Opinion leader generated and endorsed evidence summaries; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN
Brief Summary: About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.

Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.

Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.

Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.


Options:
A: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case-based customized learning | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case based customized learning + leader feedback | Intervention Type: BEHAVIORAL; Name: Simulated case-based customized learning; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Simulated case based customized learning + leader feedback; Assigned to Arm(s): Group C
B: Intervention Type: BEHAVIORAL; Name: Evidence summaries endorsed by local opinion leaders; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Opinion leader generated and endorsed evidence summaries; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Individual Versus Standard rFSH Dose for Controlled Ovarian Stimulation and Intrauterine Insemination. A Prospective Randomised Multi Centre Study
Brief Summary: The purpose of this study is to test if recombinant follicle stimulating hormone (rFSH) given in individual doses, according to a nomogram we have constructed based on our results from a previous study, results in more patients maturing 2-3 follicles compared to standard dose.


Options:
A: Intervention Type: DEVICE; Name: Electronic Medical Record (EMR) to clinician's in-basket; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Automated Voice Message (AVM) reminder to patient's phone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Pharmacy Team phone call-letter followup; Assigned to Arm(s): N/A
B: Arm Label: "Individual" or "standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: rFSH drug dose | Arm Label: "Standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: "Standard" rFSH dose | Intervention Type: DRUG; Name: rFSH drug dose; Assigned to Arm(s): "Individual" or "standard" rFSH dose | Intervention Type: DRUG; Name: "Standard" rFSH dose; Assigned to Arm(s): "Standard" rFSH dose
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: antipsychotic dose increase | Arm Label: TAU; Type: PLACEBO_COMPARATOR; Interventions: Other: no intervention | Intervention Type: DRUG; Name: antipsychotic dose increase; Assigned to Arm(s): A | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): TAU
D: Arm Label: Standard IWPC warfarin dosing algorithm; Type: ACTIVE_COMPARATOR; Interventions: Genetic: IWPC adapted genotype-guided dosing algorithm for warfarin | Arm Label: Modified IWPC warfarin dosing algorithm; Type: EXPERIMENTAL; Interventions: Genetic: Modified IWPC genetic-guided warfarin dosing algorithm | Arm Label: Historical controls; Type: OTHER; Interventions: Other: Standard of care treatment | Intervention Type: GENETIC; Name: IWPC adapted genotype-guided dosing algorithm for warfarin; Assigned to Arm(s): Standard IWPC warfarin dosing algorithm | Intervention Type: GENETIC; Name: Modified IWPC genetic-guided warfarin dosing algorithm; Assigned to Arm(s): Modified IWPC warfarin dosing algorithm | Intervention Type: OTHER; Name: Standard of care treatment; Assigned to Arm(s): Historical controls

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Individual Versus Standard rFSH Dose for Controlled Ovarian Stimulation and Intrauterine Insemination. A Prospective Randomised Multi Centre Study
Brief Summary: The purpose of this study is to test if recombinant follicle stimulating hormone (rFSH) given in individual doses, according to a nomogram we have constructed based on our results from a previous study, results in more patients maturing 2-3 follicles compared to standard dose.


Options:
A: Arm Label: HP-hMG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meropur 150 a day | Arm Label: rFSH plus rLH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gonal-f 150 plus Luveris 150 | Intervention Type: DRUG; Name: Meropur 150 a day; Assigned to Arm(s): HP-hMG | Intervention Type: DRUG; Name: Gonal-f 150 plus Luveris 150; Assigned to Arm(s): rFSH plus rLH
B: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)
C: Arm Label: "Individual" or "standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: rFSH drug dose | Arm Label: "Standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: "Standard" rFSH dose | Intervention Type: DRUG; Name: rFSH drug dose; Assigned to Arm(s): "Individual" or "standard" rFSH dose | Intervention Type: DRUG; Name: "Standard" rFSH dose; Assigned to Arm(s): "Standard" rFSH dose
D: Arm Label: Letrozole/IUI; Type: EXPERIMENTAL; Interventions: Drug: Letrozole/IUI | Arm Label: CC/IUI; Type: ACTIVE_COMPARATOR; Interventions: Drug: CC/IUI | Intervention Type: DRUG; Name: Letrozole/IUI; Assigned to Arm(s): Letrozole/IUI | Intervention Type: DRUG; Name: CC/IUI; Assigned to Arm(s): CC/IUI

Answer: C